Objectives: Due to the discovery in the 1980s that blood
transfusion can transmit HIV, there has been increased interest in
technologies that reduce the amount of allogeneic blood used during and after
surgery. These technologies include drugs (aprotinin, tranexamic acid,
epsilon-aminocaproic acid, erythropoietin), devices (cell salvage), and
techniques (acute hemodilution, predeposited autologous donation). The purpose
of this study was to ascertain the degree of practice variation, if any, that
exists for eight technologies in nine countries in orthopedic and cardiac
surgery.
Methods: In each country, either all hospitals or a random sample
of hospitals with medical/surgical beds were surveyed between 1995 and
1997. Two instruments were used. The first instrument was a postcard that
asked recipients whether the technologies were currently being used in their
hospital for orthopedic and/or cardiac surgery to reduce perioperative
allogeneic transfusion. The second questionnaire elicited information
regarding the degree of use both in qualitative and quantitative terms. Data
were collected, entered, and analyzed in each country, with summary results
submitted to the Canadian coordinating center on a standardized data
collection form.
Results: Pharmaceuticals were generally used in a much smaller
proportion of hospitals in orthopedic than in cardiac surgery. Aprotinin and
tranexamic acid were the drugs most frequently used in cardiac surgery.
Nonpharmacological technologies were used to a greater degree than drugs in
orthopedic surgery, although there was wide variation among technologies and
countries. Acute hemodilution and cell salvage were used in a greater
proportion of hospitals for cardiac surgery than orthopedic surgery.
Conclusions: The results of this survey indicate that there is
considerable practice variation in the use of technologies to minimize
exposure to perioperative allogeneic transfusion within and between countries.